Farmas USA

AMRN, velas 30 min desde la subida.

El grafico esta bastante claro.

NVAX

8,58$ (+4,38%) Con 23.166 títulos.

OXGN

Un par de artículos. Empieza el ruido mediático.

http://www.talkmarkets.com/contributor/small-cap-gems/blog/stocks--equities/is-oxigene-the-cheapest-biotech-on-the-nasdaq?post=61781

http://www.myroadtomillions.com/stock-ideas/oxgn-due-diligence-post/

Dilución y caída en valores con poco float.

(copiado del segundo articulo de mi post anterior)

It is important to realize that in today’s market, the big boys (hedge funds, institutions, etc) are a lot more sophisticated than they have ever been, go to Chat With Traders and listen to a few podcasts from excellent traders and you will understand what I mean by sophistication. Basically, OXGN had a very few outstanding shares (OS) of around 20M shares PRE offering and now their OS is approximately 27M shares after. At a market cap of around $32M PRE offering, a $10M raise equates to about 6 million shares or 30% of the OS. Using the ideas presented in the Business Insider article above it looks like institutional investors wanted to build a position in OXGN ahead of the upcoming catalysts, but it would have been impossible for them to build such a large position with a low average given the very small amount of shares traded daily. Therefore, the institutional investors agree to a direct offering from the company at an agreed upon price. In OXGN’s case that price was $1.71/share. Overall market reaction to news of a raise is usually negative because you are diluting existing shareholders, people cant understand why they are raising, they panic, and then they sell their shares which cause the price to drop further. On top of that, the institutional investors that bought the offering begin to short sell shares to get the price even lower. At the same time they are shorting the stock, they are building up their long position at a lower average. Once they have accumulated all of their position at an average that is right for them they will begin to cover their short position. This cause the stock price to rise and rise and rise into the next catalyst. When the news finally hits the market, now all of a sudden their is a lot of new buyers that want in and the institutional investors dump their shares on the new retail buys transferring the shares from strong hands to weak hands.

NVAX

¡Me va a salir cara la compra adicional de hoy!

http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#nvax
1:38 am Novavax presents new data from non-human primate Ebola challenge (NVAX) : Co announced presented new data from a second non-human primate study. In that study, animals received two injections of a 5 g dose of Novavax' Ebola GP Vaccine together with its proprietary Matrix-M adjuvant and were then challenged with a lethal dose of the Ebola virus. Similar to the previous NHP study, the challenge was lethal for the control animals, whereas the animals immunized with Novavax' EBOV GP Vaccine remain healthy 18 days post challenge.

Pues no la compres!!! o espera a ver si cierra el gap de hoy!!

NVAX

MUY interesante, Ana. 

Muy interesante ver escrito lo que ya sabemos que nos intentan hacer una y otra vez las manos fuertes.

OXGN

Synta Pharmaceuticals Corp en 2,30... dan gnas de pegarla un tirito.

Tengo una bala y estoy dudando entre esta y NVAX, pero esta última si abre con gap no correré detrás de ella.